ClinicalTrials.gg
CompletedNCT01440686HL-032Updated Oct 16, 2012

Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

A Phase 1 interventional study of Somatropin and Placebo in Growth Hormone Deficiency, sponsored by HanAll BioPharma Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-16.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
35th of 60
40 · median 66
Started
2011
the only one that year
Phase 1
6 of 60
none open now
Registered
39th of 60
by date

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 35th largest by planned enrollment, is the only one that started in 2011, is one of 6 in phase 1, and was the 39th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • Male
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • Age(yr)between 19 and 50
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Known to Octreotide or hGH(human growth hormone)
  • History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal, Neurological/Psychic, cancer
  • Alcoholic, smokers or drug abusers
  • Other conditions which in the opinion of the investigator preclude enrollment into the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HL-032 30mg

    A single dose 30mg administered orally

    Drug: Somatropin · Drug: Placebo

  • Experimental
    HL-032 60mg

    A single dose 60mg administered orally

    Drug: Somatropin · Drug: Placebo

  • Experimental
    HL-032 120mg

    A single dose 120mg administered orally

    Drug: Somatropin · Drug: Placebo

Interventions

  • A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin

  • DrugPlacebo

    Tablets, oral administrations

06

What researchers measure

Primary outcomes

  1. Area under the serum hGH(human growth hormone)concentration-time curve

    Time frame: From 0 to the time of the last quantifiable concentration over a 32-hour sampling period

  2. Maximum observed serum hGH concentration

    Time frame: Over a 32-hour sampling period

Secondary outcomes

  1. Area under the effect(IGF-1, IGFBP-3, NEFA)curve

    Time frame: From time 0 to the time of the last concentration(AUECO-t) over 32-hour sampling period

  2. Maximum IGF-1, IGFBP-3, NEFA effect

    Time frame: Over a 32-hour sampling period

07

Study locations

1 site
  • Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute
    Seoul, 110-744, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2011
First posted
Sep 26, 2011
Start
Sep 2011
Primary completionActual
Dec 2011
CompletionActual
Jan 2012
Last update
Oct 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01440686
Responsible party
Sponsor
First posted
Sep 26, 2011
Start date
Sep 2011
Primary completion
Dec 2011
Completion
Jan 2012
Last update
Oct 16, 2012

Study contacts

Kyung-Sang Yu, Medicine
principal investigator · Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion